Table 2.

Annual rates of invasive breast cancer—NSABP STAR Trial (P-2)

Participant characteristic at baselineNumber of eventsRate per 1000RR*RR (95% CI)
TamoxifenRaloxifeneTamoxifenRaloxifeneDifference
Age at entry (years)
    ≤4910151.842.80−0.961.530.64–3.80
    50-591251554.095.03−0.941.230.97–1.57
    ≥601121404.475.48−1.011.220.95–1.58
History of lobular carcinoma in situ
    No1972533.544.50−0.961.271.05–1.54
    Yes50579.1410.34−1.201.130.76–1.69
History of atypical hyperplasia
    No1872183.904.52−0.621.160.95–1.42
    Yes60924.586.79−2.211.481.06–2.09
5-year predicted breast cancer risk (%)
    ≤3.0061812.393.21−0.821.340.95–1.90
    3.01-5.0084914.434.63−0.201.050.77–1.42
    ≥5.011021386.138.17−2.041.331.02–1.74
No. 10 relatives with breast cancer
    0821054.776.17−1.401.290.96–1.75
    11121353.514.10−0.591.170.90–1.51
    ≥253704.445.96−1.521.340.93–1.96
Total2473104.045.02−0.981.241.05–1.47

Abbreviations: CI, confidence interval; NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

  • *Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.

  • Rate in the tamoxifen group minus rate in the raloxifene group.